Complete financial analysis of CellSource Co., Ltd. (4880.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CellSource Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Globus Spirits Limited (GLOBUSSPR.NS) Income Statement Analysis – Financial Results
- New Guinea Gold Corporation (NGUGF) Income Statement Analysis – Financial Results
- Shibuya Corporation (6340.T) Income Statement Analysis – Financial Results
- India Cements Capital Limited (INDCEMCAP.BO) Income Statement Analysis – Financial Results
- Anfield Energy Inc. (0ADN.F) Income Statement Analysis – Financial Results
CellSource Co., Ltd. (4880.T)
About CellSource Co., Ltd.
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.51B | 4.27B | 2.92B | 1.86B | 1.61B | 1.21B | 519.06M |
| Cost of Revenue | 1.33B | 1.21B | 848.21M | 596.52M | 457.99M | 336.80M | 219.14M |
| Gross Profit | 3.18B | 3.06B | 2.07B | 1.26B | 1.15B | 875.93M | 299.93M |
| Gross Profit Ratio | 70.60% | 71.70% | 70.97% | 67.85% | 71.58% | 72.23% | 57.78% |
| Research & Development | 72.45M | 87.56M | 71.16M | 10.82M | 8.00M | 6.88M | 4.09M |
| General & Administrative | 453.86M | 324.05M | 204.85M | 169.86M | 145.47M | 247.16M | 77.63M |
| Selling & Marketing | 103.89M | 101.43M | 93.88M | 122.88M | 199.66M | 183.13M | 23.19M |
| SG&A | 1.87B | 425.48M | 298.73M | 292.74M | 345.13M | 430.28M | 100.82M |
| Other Expenses | 25.00M | 980.20M | 711.69M | 539.84M | 473.53M | 143.67M | 2.00K |
| Operating Expenses | 1.96B | 1.49B | 1.08B | 843.40M | 826.65M | 580.83M | 140.76M |
| Cost & Expenses | 3.29B | 2.70B | 1.93B | 1.44B | 1.28B | 917.63M | 359.90M |
| Interest Income | 13.00K | 7.00K | 2.00K | 8.00K | 1.00K | 1.00K | 0.00 |
| Interest Expense | 379.00K | 11.00K | 136.00K | 286.00K | 49.00K | 547.00K | 0.00 |
| Depreciation & Amortization | 66.38M | 61.15M | 54.26M | 63.36M | 62.05M | 15.09M | 10.77M |
| EBITDA | 1.31B | 1.64B | 1.06B | 476.46M | 365.44M | 309.64M | 169.93M |
| EBITDA Ratio | 28.96% | 38.41% | 35.68% | 23.68% | 20.11% | 25.43% | 32.74% |
| Operating Income | 1.22B | 1.57B | 992.44M | 415.55M | 326.94M | 295.09M | 159.16M |
| Operating Income Ratio | 27.08% | 36.76% | 33.96% | 22.40% | 20.29% | 24.33% | 30.66% |
| Total Other Income/Expenses | 18.18M | 12.59M | 13.93M | -2.74M | -23.60M | -543.00K | -160.00K |
| Income Before Tax | 1.24B | 1.58B | 1.01B | 412.81M | 303.35M | 294.55M | 158.84M |
| Income Before Tax Ratio | 27.48% | 37.05% | 34.44% | 22.25% | 18.82% | 24.29% | 30.60% |
| Income Tax Expense | 316.54M | 565.80M | 354.97M | 138.73M | 103.74M | 101.15M | 47.44M |
| Net Income | 923.14M | 1.02B | 651.40M | 274.08M | 199.61M | 193.40M | 111.40M |
| Net Income Ratio | 20.47% | 23.82% | 22.29% | 14.77% | 12.39% | 15.95% | 21.46% |
| EPS | 48.88 | 54.54 | 35.17 | 15.19 | 11.55 | 14.92 | 6.45 |
| EPS Diluted | 47.93 | 52.98 | 33.91 | 14.33 | 11.55 | 14.92 | 6.45 |
| Weighted Avg Shares Out | 18.88M | 18.66M | 18.52M | 18.05M | 17.28M | 12.96M | 17.28M |
| Weighted Avg Shares Out (Dil) | 19.26M | 19.21M | 19.21M | 19.13M | 17.28M | 12.96M | 17.28M |
No news found for: 4880.T
Source: https://incomestatements.info
Category: Stock Reports